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hyperproliferative, apoptosis-resistant, and proinflammatory
phenotype of microvascular endothelial cells and smooth muscle
cells isolated from patients with pulmonary arterial hypertension
(PAH). A previous study demonstrated that low-plasma high-
density lipoprotein cholesterol (HDL-C) was associated with
higher mortality and clinical worsening outcomes, including
hospitalization and lung transplantation in the patients with
PAH (2). Administration of RVX-208 in the patients with
coronary artery disease for 12 weeks was significantly associated
with modulation of lipids metabolism, including increases in
HDL-C level and concentration of large HDL particles (3).
Hence, we considered whether, first, the change of HDL-C would
be one feasible clinical biomarker to reflect the responsiveness of
drugs or prognostic value in the patients with PAH. For example,
the enhancement of HDL-C in plasma through RVX-208
treatment would improve the clinical outcomes in patients with
PAH, and second, based on the beneficial effects of RVX-208 on
the amelioration of vascular remodeling, pulmonary
hemodynamics, and right ventricle in different preclinical models
of PAH (1), the casual link among these observed outcomes,
efficacy of RVX-208 therapy, and the change of HDL-C level or
HDL components could be worthy of further investigation.
Metabolic disorders characterized by increases of
proinflammatory cytokine IL-6 level in lung and circulating
leptin could exacerbate pulmonary hypertension as a result of
left heart disease (PH-LHD), and patients diagnosed with this
type of PAH have more severe symptoms and worse prognosis
relative to patients with LHD alone (4). Notably, in light of
pulmonary vascular remodeling in such a novel preclinical model
of PH-LHD relieved by metformin though improvement of
metabolic states and decrease of inflammation, and positive
effects of RVX-208 on the regulation of both inflammation
and metabolism (3, 4), we thought that providing more insights
about the efficacy of RVX-208 in PH-LHD might be more
favorable to its clinical use. Epigenetic regulation plays a key
role in the pathogenesis of PAH, such as drug/toxin
susceptibility, female predominance, and quasimalignant lung
vessel cell growth (5). In view of BET protein BRD4
(bromodomain-containing protein 4) as an epigenetic driver of
inflammation and atherogenesis, the reduction of vascular
inflammation in vitro and major adverse cardiac events in
the patients with cardiovascular disease by the administration
of RVX-208 has been considered to rely on a BET-dependent
epigenetic mechanism (6). Therefore, we considered that
clarifying additional epigenetic mechanisms underlying the
therapeutic process of RVX-208 in PAH might be in favor of
identifying putative biomarkers and risk or resilience factors for
making new-type prevention and treatment to answer epigenetic-
sensitive clinical challenges in PAH. n
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Reply to Ning et al.
From the Authors:
We thank Ning and colleagues for their suggestions aimed at
exploring whether RVX-208 therapy in pulmonary arterial
hypertension (PAH) is associated with enhanced concentration of
plasmatic high-density lipoprotein cholesterol (HDL-C), whether
these anticipated changes contribute to the improvement of vascular
remodeling and pulmonary hemodynamics seen in our models,
whether the circulating HDL-C level can be used as a clinical
biomarker in future PAH clinical studies, and whether our findings
could be extrapolated to other forms of pulmonary hypertension
(PH).
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Commons Attribution Non-Commercial No Derivatives License 4.0
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As mentioned by Ning and colleagues, reduced HDL-C levels
characterize patients with PAH and are associated with worse
prognosis (1). Interestingly, RVX-208 (apabetalone) was
originally developed as a lipid-modifying agent, inducing
hepatic synthesis of apoA-I (apolipoprotein A-I) and enhancing
the cholesterol efflux capacity of HDL. However, early studies
evaluating the administration of apabetalone in patients with
coronary artery disease (CAD) revealed modest elevation of
apoA-I and HDL-C (2), suggesting that apabetalone may have
actions beyond those on lipoproteins. As a result of their ability
to bind acetylated histone tails, as well as to interact and
modulate the activity of many regulators of transcription,
members of the bromodomain and extra-terminal domain
protein family such as BRD4 (bromodomain-containing protein
4) are implicated in many cellular processes and cell growth. As
such, their inhibition is expected to exert pleiotropic actions,
concomitantly affecting different aspects of PAH
pathophysiology.
We consistently documented previously that BRD4 inhibition
reversed the oncogenic NFAT, Bcl-2, and survivin upregulation,
restoring the PAH–pulmonary artery smooth muscle cell
proliferation/apoptosis imbalance and improving pulmonary
hemodynamics in PH rat models (3). We also documented that
BRD4 expression was increased in coronary arteries of patients
with PAH, contributing to vascular remodeling and the
development of concomitant CAD (4). Interestingly, BRD4 is also
known to regulate RUNX2, which accounts for calcification
lesions seen in PAH (5, 6). Of note, the effects of BRD4 inhibition
on PAH and CAD were at least in part mediated through its
effects on metabolism and inflammation (4, 7). As proposed by
Ning and colleagues, whether these findings could be extrapolated
to other types of PH characterized by inflammatory and
metabolic disturbances such as group 2 PH occurring in the
setting of a metabolic syndrome (8) certainly represents a
research priority, given the significant unmet medical needs for
these patients.
Obviously, the enhanced HDL-C levels after RVX-208
treatment may also have contributed by itself to the structural
and hemodynamic improvements reported in our PAH models
(4, 7). Consistent with the pleiotropic effects described here,
however, the recent pooled analysis of clinical trial phase 2
studies in patients with CAD confirmed that apabetalone
reduced the incidence of major adverse cardiovascular events,
despite marginal effects on their lipid profile (2). Of interest,
exploratory analyses suggested that this reduction in major
adverse cardiovascular events was most predominantly observed
in patients with low HDL-C, elevated inflammation levels, or
diabetes at the baseline. As HDL-C positively correlates with
systemic inflammatory markers (IL-1b, IL-6, MCP-1 [monocyte
chemoattractant protein-1], and TNFa [tumor necrosis factor
a]), apabetalone did not translate either to regression of
coronary atherosclerosis volume in patients with CAD or to
changes in blood glucose and had only a marginal benefit on
inflammation levels (2). The exact mechanisms by which
apabetalone prevented major adverse cardiovascular events
remains elusive. Accordingly, in addition to accumulating
mechanistic insights, whether baseline alterations in DNA
repair pathways, procalcification processes, inflammation
and metabolic defects, or changes upon treatment identify
potential biomarkers predicting or paralleling response to
BRD4 inhibition, allowing the molecular stratification of
patients with PAH and precision medicine will be explored in
our ongoing clinical study (APPRoAcH; clinical trial registered
with www.clinicaltrials.gov [NCT 03655704]), evaluating
apabetalone in PAH. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
Steeve Provencher, M.D., M.Sc.*
Olivier Boucherat, Ph.D.










Leiden University Medical Center
Leiden, the Netherlands
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Improving Lung Function in Severe Heterogenous
Emphysema with the Spiration Valve System:
Still a Great Need to “EMPROVE”
To the Editor:
We read with keen interest the results of a randomized controlled
trial of the Spiration Valve System in patients with severe
emphysema by Criner and colleagues (1). We congratulate the
authors for presenting a well-designed study on an important
clinical question. It has been previously reported that use of
endobronchial valves in severe emphysema leads to improvement
in FEV1 compared with placebo, similar to the results found in
the present study (2). However, some important points regarding
the reported results need careful consideration and further
discussion.
Although the authors report significant improvement in
FEV1 compared with baseline on 6-month follow-up in the
valve group, the overall responder rate is only 37%; that is,
only approximately one-third of all patients who received the
valve actually demonstrated benefit in airflow. Similarly, although
the patient-centered outcomes (i.e., dyspnea and quality of life)
improved in the valve group, they did so in only 53% and 54%
of subjects, respectively, at 6 months. We feel that this
response rate is extremely low by any standard, especially
considering the high cost and potential complications
associated with valve placement. Therefore, it would be
desirable to interpret these results in the proper perspective,
based on cost benefit.
Considering the patient population in which
endobronchial valve therapy is being considered (i.e., those
with severe airflow limitation, limited exercise capacity, and
receiving long-term oxygen therapy), it may be worthwhile to
identify predictors of nonresponse in the endobronchial valve
therapy group in an attempt to identify patients most likely to
derive benefit from this intervention. This may have important
implications for rationalizing clinical practice of emphysema
management. n
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Reply to Jain et al.
From the Authors:
We thank Dr. Jain and colleagues for their comments about
our study. We wholeheartedly agree that refining the patient
population most likely to benefit from this or any other therapy is
the goal of personalized patient care. The cost of care, especially in
the case of patients with emphysema, is also of prime importance.
However, we would like to emphasize that despite the severity of
the patient group studied in EMPROVE (patients with severe and
irreversible airflow obstruction [FEV1, 28–30% predicted],
hyperinflation [residual volume, 207–213% predicted], and
.60% emphysema severity in the targeted lobes), patients with
valve treatment were sevenfold more likely to achieve .15%
improvement in FEV1 at 1 year compared with the control
group receiving optimal medical therapy (1). In addition, as
pointed out by Dr. Jain, more than half the subjects exceeded
the minimally important changes in dyspnea and quality of life.
This was balanced against the complication of pneumothorax,
a treatable consequence of endobronchial valve treatment with
total lobar occlusion in subjects with fissure integrity. We believe
it is also important to consider the alternative therapies used to
treat patients at this stage of their disease and their symptom
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